SIRT5 affects prostate cancer proliferation, progression and survival enhancing Acetyl-CoA acetyltransferase 1 activity leading to MAPK pathway promotion and ultimately to Matrix metallopeptidase 9 (MMP-9) and cyclin D1 expression [65]. The gene discussed is MMP9; the disease is prostate carcinoma.